Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2023-02-13 Major Shareholding Noti…
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-13 English
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by Mereo BioPharma Group plc. It registers additional shares under the company's equity incentive plans. Form S-8 is a specific SEC filing used to register securities to be offered to employees under employee benefit plans. The document includes details about the plans, incorporation by reference of prior filings, and legal indemnification provisions. It is not a financial report, earnings release, or management discussion, nor is it an announcement of a report. It is a capital market filing related to share registration for employee stock plans, which aligns with capital/financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual filing, not just an announcement or certification. Confidence is high due to clear identification of Form S-8 and its purpose.
2023-01-24 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group plc, with the SEC. It provides third quarter 2022 financial information including cash position and net cash burn, but it is a brief report and does not contain detailed financial statements or comprehensive analysis. The length is 4557 characters, which is relatively short. The document is a periodic report for a quarter but does not contain full financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR). It is also not an announcement of a report publication but the report itself. Form 6-K is typically used for current reports by foreign private issuers and often classified as Regulatory Filings (RNS) unless it contains substantive financial data. Given the brief financial data and the nature of Form 6-K, the best fit is Regulatory Filings (RNS).
2022-11-10 English
6-K
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group plc, with the SEC. The content focuses on the departure and appointment of directors and officers on the company's Board of Directors, including committee chair appointments and qualifications of directors. There is no financial data, earnings information, or detailed report content. The document is an announcement of changes in the company's board and management structure. According to the filing definitions, this fits the category of Board/Management Information (MANG). The document length is 3370 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the classification is MANG with high confidence.
2022-11-10 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group plc, with the SEC. It includes unaudited condensed consolidated financial statements as of June 30, 2022, and Management's Discussion and Analysis (MD&A) of financial condition and results of operations. The Form 6-K is a report of foreign private issuers to provide current information, often including interim financial data. The document explicitly states it contains unaudited condensed consolidated financial statements and MD&A for a period shorter than a full fiscal year (June 30, 2022). The length is 3563 characters, which is relatively short but contains substantive financial data and analysis. According to the rules, an interim or quarterly report must contain actual financial statements or substantive financial data and analysis, which this document does. Therefore, this filing is best classified as an Interim / Quarterly Report (IR).
2022-11-02 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group plc, with the SEC. It reports receipt of a notification letter from Nasdaq regarding the company's failure to maintain the minimum bid price for its ADSs, explaining the compliance period and potential delisting process. The document is an announcement of a regulatory event related to listing compliance, not a full financial report or earnings release. It is also relatively short (3501 characters) and includes a press release as an exhibit. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement and does not contain financial statements or detailed financial data. It is not a Delisting Announcement (DLST) because the delisting is not immediate but a notification of deficiency and compliance period.
2022-11-02 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.